Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation.

Summary

This mechanistic study shows simvastatin binds RyR1, stabilizes its open state, and induces leaky channels leading to muscle weakness, particularly in a RyR1-T4709M mutation model. A Rycal, which stabilizes the closed state of RyR1, prevented simvastatin-induced weakness, suggesting a potential therapeutic strategy for statin intolerance.

Key Findings

• High-resolution structures revealed simvastatin binding in the RyR1 pore region, stabilizing the open conformation.
• Simvastatin activated RyR1 and caused muscle weakness in a RyR1-T4709M knock-in mouse model via leaky channels.
• Co-treatment with a Rycal prevented simvastatin-induced muscle weakness by stabilizing the closed channel state.

Clinical Implications

Supports genetic/phenotypic risk stratification for statin intolerance (e.g., RyR1 variants) and motivates evaluation of Rycals to enable statin therapy in high-risk patients. Encourages vigilance for myopathy in patients with known RyR1-related disorders.

Limitations

• Preclinical study; no randomized clinical trials evaluating Rycals in statin-intolerant patients
• Findings centered on simvastatin and one RyR1 mutation; generalizability to other statins and genotypes requires testing

Future Directions

Conduct genotype-informed clinical trials of Rycals in statin-intolerant populations; map statin–RyR1 interactions across statin classes and RyR1 variants; develop biomarkers of RyR1 leak in humans.